Sridhar Nonavinkere Srivatsan

7PUBLICATIONS
34CO-AUTHORS
Medical infection agents (incl. prions)Liquid biopsiesRegenerative medicine (incl. stem cells)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 06, 2026
Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.

|Jun 04, 2026
Long-read cDNA sequencing reveals novel isoforms and spliceosome-mutant-enriched transcripts in AML and MDS.

|May 06, 2026
U2af1S34F and U2af1Q157R myeloid neoplasm-associated hotspot mutations induce distinct hematopoietic phenotypes in mice.

|Apr 09, 2026
Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage.

Claudia Cabrera Pastrana, Sridhar Nonavinkere Srivatsan, Michael O Alberti

|May 19, 2025
U2af1 S34F and U2af1 Q157R myeloid neoplasm-associated hotspot mutations induce distinct hematopoietic phenotypes in mice.

Michael O Alberti, Sridhar Nonavinkere Srivat, Jin Shao

|Oct 04, 2024
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.

Meagan A Jacoby, Eric D Duncavage, Ajay Khanna

Pageof 2

Frequent Collaborators

6 joint publications

Matthew J Walter

2 joint publications

Timothy A Graubert

2 joint publications

Michael O Alberti

2 joint publications

Claudia Cabrera Pastrana